![]() |
市場調查報告書
商品編碼
1499318
全球 VISTA 抑制劑市場:臨床試驗和市場機會洞察 (2024)Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024 |
隨著研究和開發領域的發展、技術的進步和研究人員知識庫的增加,人們發現許多蛋白質在許多疾病的發生和進展中發揮核心作用。其中,免疫檢查點蛋白因其在抑制抗癌免疫反應中發揮作用而引起人們的關注,並已成為一個有希望的治療標靶。 VISTA 蛋白是最新發現的檢查點蛋白之一,具有區別於其他檢查點蛋白的特殊特性,並顯示出治療癌症和發炎性疾病的潛力。因此,VISTA 已成為多項研究的主題,製藥公司正在透過開發針對 VISTA 的藥物來補充這些努力。
T 細胞活化的 V 結構域 Ig 抑制因子,通常稱為 VISTA,是一種免疫檢查點蛋白,對免疫系統發揮抑制和刺激作用。已知的其他免疫檢查點僅能負向調節免疫反應,而後者正是 VISTA 的獨特之處。抑制 VISTA 的抑制功能已成為癌症治療的顯著方法,而 VISTA 的免疫系統刺激功能已在小鼠模型中得到廣泛研究。
根據這些研究,製藥和生技公司正在專注於開發 VISTA 的治療介入措施,主要用於癌症治療。然而,該領域並非沒有課題,許多課題已退出臨床開發。然而,新一代 VISTA 抑制劑正在開發中,以解決這些候選藥物的缺點。
本報告調查了全球 VISTA 抑制劑市場,並提供了市場概況,包括藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司競爭格局。
Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
With evolution in the research and development domain, along with technological advancements and the increasing knowledge bank of researchers, a number of proteins have been discovered to play central roles in development and progression of many diseases. Among these, immune checkpoint proteins have especially gained attention for their role in suppressing anti-cancer immune responses and have emerged as promising therapeutic targets. The VISTA protein is one of the newest checkpoint proteins to be discovered, which has showed potential in treating both cancer and inflammatory diseases because of its extraordinary properties that make it different from its fellow checkpoint proteins. As a result, it has become the subject of several research studies, with pharmaceutical companies complementing these efforts with the development of drugs targeting VISTA.
V-domain Ig suppressor of T cell activation, commonly known as VISTA, is an immune checkpoint protein which exerts both inhibitory and stimulatory effects on the immune system. Other identified immune checkpoints are only known to negatively regulate immune responses, which is why the latter makes VISTA unique. Blocking its inhibitory functions has emerged as a hot approach in the treatment of cancer, while its immune system stimulatory functions have been explored widely in murine models.
With these research studies serving as the foundation, several pharmaceutical and biotechnology companies have been focusing on the development of therapeutic interventions that target the VISTA, mainly for the management of cancer, given that most clinical studies were conducted to elucidate its role in cancer. However, the field has not been without challenges, with many candidates being withdrawn from clinical development. However, new generation VISTA inhibitors are being developed to address the shortcomings of these candidates.
CA-170, developed by Aurigene Oncology and Curis, marks a significant advancement in the landscape of VISTA-targeted therapies. CA-170 is a first-in-class oral small molecule that directly targets both PD-1/PD-L1 and VISTA pathways. It is currently undergoing phase 2/3 clinical trials in India for the management of non-squamous non-small cell lung cancer, making it the candidate farthest ahead in the pipeline of VISTA-targeted therapies. While CA-170 has shown anti-tumor activity in multiple preclinical models, results from these ongoing clinical trials are yet to be revealed by Aurigene or Curis.
In addition to Aurigene and Curis, several research institutes, and biotechnology and pharmaceutical companies are actively pursuing VISTA inhibitors; these include Cancer Prevention and Research Institute of Texas, Kineta, Sensei Biotherapeutics, Washington University among others. Therefore, the current market for VISTA targeted therapies is witnessing a high level of competition and innovation, albeit with smaller companies dominating and larger companies waiting for breakthroughs before making their way into the market.
At present, cancer, mainly solid tumors, are dominating the research and development landscape of VISTA-targeted therapies. However, ongoing research has also associated the functions of VISTA with autoimmune and inflammatory disorders, wherein aberrant immune system activation damages tissue. This can however, with averted with the use of VISTA agonists, which can help expand the potential of VISTA as a therapeutic target to diseases mediated by the immune system. Additionally, modulation of VISTA activity has also been linked to viral infection through research findings indicating the VISTA plays a role in regulating the immune responses in viral infections. Therefore, as research findings continue linking VISTA functions to new indications, it becomes increasingly evident that researchers are yet to unravel the complexities of VISTA.
In conclusion, the landscape of VISTA-targeted therapeutics is characterized by active research, early-stage clinical development, and growing interest from both the scientific community and the pharmaceutical sector. As research progresses, VISTA inhibitors emerge as a beacon of innovation, holding up hope not only for cancer treatments but also for viral infections, autoimmune illnesses, and other ailments.
(US10745467B2) - Grant & Expiration Year